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ABSTRACT 
Omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) from fish and fish oils appear to protect against coronary heart 
disease: their dietary intake is in fact inversely associated with cardiovascular disease morbidity/mortality in population 
studies. Recent evidence suggests that at least a part of this protective effect is mediated by a relatively small but sig-
nificant decrease in blood pressure (BP) level. In fact, omega-3 PUFAs exhibit wide-ranging biological actions that 
include regulating both vasomotor tone and renal sodium excretion, partly competing with omega-6 PUFAs for com-
mon metabolic enzymes and thereby decreasing the production of vasoconstrictor rather than vasodilator and 
anti-inflammatory eicosanoids. PUFAs also reduce angiotensin-converting enzyme (ACE) activity, angiotensin II for-
mation. We retrospectively evaluated the long-term effect of a omega-3 PUFAs supplementation on the blood pressure 
level of 91 hypertriglyceridemic subjects with untreated normal-high blood pressure that were prescribed a 3 grams 
omega-3 PUFAs supplementation in order to improve their plasma lipid pattern. After 24 months of treatment, systolic 
blood pressure (SBP) meanly decreased by 2.6 +/− 2.5 mmHg (p = 0.001) and diastolic blood pressure (DBP) by 1.4 +/− 
3.1 mmHg (p < 0.001), while basal heart rate decreased by 4.1 +/− 4.6 bpm (p < 0.001). Both SBP and DBP reduction 
were significantly related to the baseline SBP (p < 0.001) and DBP (p < 0.001), respectively. Diastolic blood pressure 
change was also inversely related to the patient’s age (p = 0.004). No significant difference was perceived in the meta-
bolic syndrome subgroup. In our retrospective study, highly purified omega-3 PUFAs long-term supplementation is 
associated with a significant reduction in SBP, DBP, and basal heart rate in hypertriglyceridemic patients with nor-
mal-high blood pressure. The main determinants of the omega-3 PUFAs anti-hypertensive effect appear to be the basal 
blood pressure level and age. Future research will clarify if omega-3 PUFAs supplementation could improve the anti-
hypertensive action of specific blood pressure lowering drug classes and of statins. 
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1. Introduction 
Dietary factors play a major role in the pathogenesis of 
essential hypertension. In fact several lines of evidence 
suggest that supplementation of diet with omega-3 poly- 
unsaturated fatty acids ( ω-3 PUFAs), commonly referred 
to as fish oil, may reduce blood pressure; hence, it is 
likely that animals fed 10% safflower oil with 30% ca- 
sein had higher amounts of free radicals and pro inflam- 
matory cytokines and developed hypertension as a con- 
sequence of low-grade systemic inflammation [1,2]. These 
evidences are relevant to patients with chronic renal fai- 
lure; high-protein diet enhances oxidative stress and in- 
terferes with the production of lipoxins, resolvins, pro-  
tectins, and maresins (anti-inflammatory compounds) that 
could adversely affect the underlying renal disease [3]. 
The dietary intake of ω-3 PUFAs is in fact inversely as-
sociated with cardiovascular disease morbidity/morta- 
lity in population studies [4]. However, most clinical 
trials of ω-3 PUFAs supplementation have been of insuf- 
ficient size to detect relevant blood pressure changes 
[5,6]. In the body there are two types of essential fatty 
acid (EFA), the ω-6 linoleic acid and ω-3 α-linolenic 
acid, metabolized by the same set of enzyme to give raise 
to arachidonic acid and eicosapentaenoic acid (EPA), the 
precursors of eicosanoids. Arachidonic acid, EPA and 
docosahexaenoic acid (DHA) (formed from eicosapen- 
tenoic acid) also form precursors to the anti-inflamma- 
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tory compounds that participate in several physiological 
and pathological processes [2]. 
The present study was designed to investigate the rela- 
tion between dietary supplements of purified ω-3 PUFAs 
(EPA + DHA with ratio 0.9/1.5, respectively) 3 grams 
/day and blood pressure in untreated normal-high blood 
pressure population.  
2. Methods 
From our cardiovascular prevention ambulatory, non- 
smoking subjects with untreated normal-high essential 
hypertension, but no other clinically evident disease, ex- 
cept that the hypertriglyceridemia, were screened for in- 
clusion in the our retrospectively study. In order to eva- 
luate the long-term effect of an ω-3 PUFAs supplementa- 
tion on the blood pressure level, for two years we studied 
ninety one patients, who gave signed consent. They were 
prescribed a 3 grams/day ω-3 PUFAs supplementation to 
improve their level of plasma lipids. Table 1 shows ge- 
neral characteristics of study population at baseline; while 
Table 2 shows the study flowchart. 
2.1. Clinic Blood Pressure and Pulse Rate 
Measurement 
Participants sat quiet for at least 5 min and arm circum- 
ference was measured to determine the appropriate cuff 
size. Two blood pressure readings were auscultated with 
a mercury manometer at 2 min intervals by a certified 
staff, between which pulse rate was palpated for 30 sec. 
Blood pressure reading were averaged across the two 
appointments and are referred to hereafter as “clinic” sy- 
stolic and diastolic blood pressure. 
2.2. 24-Hambulatory Blood Pressure and Pulse 
Rate Measurement 
Participants wore an ambulatory blood pressure device 
for 24 h. The device was programmed to automatically 
record blood pressure every 30 min between 7 a.m. and 
11 p.m. and every hour between 11 p.m. and 7 a.m. Sub- 
jects noted the time they went to bed at night and the 
time of arising in the morning. Using this information, 
device data were averaged during “awake” and “asleep” 
time periods. 
During the supplementation period the subjects were 
asked to reduce the intake of fat in their usual foods to 
avoid changes in weight. If they used statins only a stabi- 
lized dosage for at least 5 months and without changing 
other drug. Participants met with the researchers six times 
over two years. In each session, they got their blood 
pressure checked, provided a blood sample, and reported 
everything they had eaten and drunk in the past 24 hours. 
We also considered other factors, including participants’  
Table 1. General characteristics of study population at the 
baseline (values expressed as mean ± SD). 
Age (years) 58 ± 12 
Sex male 72% 
female 28% 
Body mass index(Kg/m²) 26.9 ± 3.91 
W C (cm) 91.09 ± 10.09 
SBP (mmHg) 138.7 ± 5.0 
DBP (mmHg) 90.3 ± 1.6 
HR (b/m) 72.0 ± 2.0 
TC (mg/dL) 232.75 ± 30.92 
HDL-C (mg/dL) 54.46 ± 17.48 
LDL-C (mg/dL) 128.55 ± 26.93 
TG (mg/dL) 248.72 ± 48.5 
FPG (mg/dL) 104.90 ± 18.14 
HbA1c (mg/dL) 5.8 ± 0.6 
Creatinine(mg/dL) 0.98 ± 1.8 
Abbreviations: WC: waist circumference; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; HR: heart rate; TC: total cholesterol; TG: trigly- 
cerides; HDL-C: high density lipoprotein cholesterol; LDL-C: low density 
lipoprotein cholesterol; FPG: fasting plasma glucose. 
 
Table 2. Study flowchart. 
Patients with metabolic syndrome n = 33 
Chart screened (n = 105) 
Not eligible (n = 5) 
Refused to participate (n = 9)
Studied (n = 91) 
Adverse event (n = 1) 
Patient withdrawal (n = 1) 
Non compliance (n = 1) 
Completed study (n = 88) 
Male n = 63 
Female n = 25 
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age, gender, alcohol consumption , physical activity, die- 
tary restrictions, supplements, and medications. 
3. Statistics 
No parametric distribution for any of the outcome vari- 
ables was assumed because of small sample size. Wil- 
coxon’s exact rank sum test and Fisher’s exact test (for 
continuous and categorical outcomes) compared the base- 
line characteristics as well as other outcomes. Only sub- 
jects who completed the study and had both baseline and 
final measurements were included in the analysis. A 
p-value of <5% was considered statistically significant. 
We did not adjust p-values for multiple comparisons 
since all the analyses were exploratory in nature. Because 
this was a retrospectively study no power calculations 
were performed, and all findings need to be confirmed in 
a larger clinical trial. All statistical analyses were per- 
formed using SAS software (Italy) [7,8]. 
4. Results 
Eighty eight subjects tolerated the supplements, as it 
showed in Table 2, the flowchart of study. One subject 
dropped out of follow-up for reasons unrelated to the 
study, other one for no compliance to the supplementa- 
tion 3 grams/day intake of omega-3 fatty acids. One pa- 
tient had dyspepsia as adverse event. None of the patients 
had an increased susceptibility to bruising. Body weight 
were similar among the study and did not change sig- 
nificantly during the course of the study. Table 3 shows 
the changes of study population’s parameters during the 
study. The subjects completing the study had no changes 
in values for routine blood counts or chemistries, except 
for a reduction in fasting triglyceride levels. Plasma lipid 
values significantly changed from the baseline after twenty 
four months of treatment; total cholesterol changed from 
232.75 ± 30.92 mg/dl to 209.1 ± 14 mg/dl (p < 0.001), 
HDL-cholesterol from 54.46 ± 17.48 mg/dl to 64.9 ± 15 
mg/dl (p < 0.001), LDL-cholesterol from 128.55 ± 26.93 
mg/dl to 116.98 ± 0.2 mg/dl (p < 0.001) and triglycerides 
from 248.72 ± 48.5 mg/dl to 136.1 ± 0.9 mg/dl (p < 
0.0001). We did not observe any specific differences that 
could lead to the creation of subgroup affected or not 
affected by metabolic syndrome. After twenty months of 
omega-3 PUFAs treatment, the basal heart rate also sig- 
nificantly decreased from 72.0 ± 2.0 bpm to 66.1 ± 0.9 
bpm (p < 0.0001). Participants with 3 grams/day intake 
of omega-3 fatty acids tended to have the lowest blood 
pressure with significantly greater reduction: SBP meanly 
decreased by –6.5 ± 2.2 mmHg (p < 0.04), DBP by –4.4 
± 0.9 mmHg (p < 0.04) .Systolic pressure decreased ear-
lier than diastolic pressure during supplementation with 3 
grams/day intake of omega-3 fatty acids. Diastolic blood 
pressure change was also inversely related to the pa-
tient’s age (p = 0.004).The effect of fish oil on blood 
pressure seemed to have reached a plateau by twenty 
months (Figure 1).That pattern was particularly strong in 
this population who didn’t have high blood pressure and 
who wasn’t already on restricted diets or medications to 
control its blood pressure. We note that omega-3 fatty 
acids didn’t appear to drastically slash blood pressure. 
But every small reduction in blood pressure counts, in- 
cluding foods rich in omega-3 fatty acids as part of a 
healthy diet, may have blood pressure benefits. Figure 2 
shows the graphical representation of the response to the 
supplementation dose of omega-3 PUFAs and the time 
needed for acting on clinical effects. Both SBP and DBP 
reduction are significantly related to the baseline SBP 
and DBP, respectively, independently from the patient 
sex (p < 0.04). Baseline triglycerides are significantly as- 
sociated with BP change, independently from the patient 
sex (p < 0.0001). Heart rate variation was significantly 
re- lated to both BP and triglycerides parameters, (p < 
0.0001 and p < 0.001, respectively). 
 
Table 3. Changes of study population’s parameters during the study (values expressed as mean ± SD). 
 Baseline 6 Months 12 Months 
Body mass index (Kg/m2) 26.9 ± 3.91 25.8 ±4.4 25.9 ± 4.3 25.9 ± 4.5 25.4 ± 4.4 
(W C (cm) 91.09 ±10.09 92.02 ±7.9 90.4 ± 9.0 89.9 ± 9.1 89.9 ± 9.0 
HR (b/m) 72.0 ± 2.0 69.9 ± 1.0* 68.9 ± 0.8* 66.9 ± 0.7∞ 66.1 ± 0.9∞ 
TC (mg/dL) 232.75 ± 30.92 223.7 ± 27.4* 218.6 ± 26.4* 215.30 ± 20.0* 209.1 ± 14* 
HDL-C (mg/dL) 54.46 ± 17.48 62.5 ± 12.0* 60.9 ± 12.0* 63.4 ± 13.0* 64.9 ± 15* 
LDL-C (mg/dL) 128.55 ± 26.93 122.34 ± 8.6* 122.9 ± 8.8* 117.57 ± 5.0* 116.98 ± 0.2* 
TG (mg/dL) 248.72 ± 48.5 194.3 ± 34.6* 179.0 ± 28.0* 152.30 ± 10.0* 136.1 ± 0.9∞ 
FPG (mg/dL) 104.90 ± 18.14 102.8 ± 16.9 101.87 ± 13.2 101.2 ± 12.0 101.0 ± 10.8 
HbA1c (mg/dL) 5.8 ± 0.6 5.7 ± 0.7 5.6 ± 0.7 5.5 ± 0.6* 5.5 ± 0.5* 
Creatinine (mg/dL) 0.98 ± 1.8 0.98 ± 1.9 0.98 ± 1.9 0.98 ± 1.2 0.98 ± 1.3 
P value: *p < .001; ∞p < .0001; Abbreviations: WC-waist circumference; HR-heart rate; TC-total cholesterol; TG-triglycerides; HDL-C: high density lipoprotein 
cholesterol; LDL-C: low density lipoprotein cholesterol; FPG: fasting plasma glucose. 
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Figure 1. Graphical representation of BP changes during 
the fish oil supplementation. Systolic blood pressure change: 
–6.5 ± 2.2; Diastolic blood pressure change: –4.4 ± 0.9; P < 
0.04. 
 
 
Figure 2. Graphical representation of the response to the 
supplementation dose of omega-3 PUFAs and the time 
needed for acting on clinical effects. 
5. Discussion 
According to the American Heart Association, Omega-3 
fatty acids benefit the heart of healthy people, and those 
at high risk of—or who have—cardiovascular disease. 
Research has shown that omega-3 fatty acids decrease 
risk of arrhythmias (abnormal heartbeats), which can 
lead to sudden death. Omega-3 fatty acids also decrease 
triglyceride levels, slow growth rate of atherosclerotic 
plaque, and produce modest reductions in blood pressure 
(slightly). The omega-3 fatty acids in fish oil seem to be 
able to expand blood vessels, and this brings blood pre- 
ssure down [9]. It appears that omega-3 PUFAs confer 
cardiovascular benefits largely through DHA and EPA 
enrichment of membrane phospholipids [10]. Ventura et 
al. showed that in patient after cardiac transplantation 
with Cycosporine-induced hypertension omega-3 fatty 
acids produced vasodilatation, reducing blood pressure 
[11]. 
In according to Theis F. et al. association of omega-3 
polyunsaturated fatty acids stabilized the atherosclerotic 
plaques improving arterial and endothelial function [12], 
and in according to Din et al. they reduced platelet ag- 
gregation [13]. Our results are in according to Mozaf- 
farian et al. who showed that the antiplatelet, antiinflam- 
matory, and triglyceride-lowering effects of omega-3 
PUFAs require relatively higher doses of DHA and EPA 
(e.g., 3 to 4 g/day), whereas some of the antiarrhythmic 
effects, improvement in heart failure can be achieved at 
lower doses (500 to 1000 mg/day) [14]. 
Although the effects of omega-3 PUFAs on C-reactive 
protein levels have been inconsistent [15], these agents 
have been shown to suppress production of pro-inflam- 
matory cytokines such as interleukin-1B, interleukin-6, 
and tumor necrosis factor-alpha [16]. When administered 
to obese patients, 1.8 g of EPA increased the levels of 
adiponectin, which can reduce inflammation and improve 
insulin sensitivity [17], in addition to the potential bene- 
ficial heart failure effects discussed earlier. Although be- 
nefits on the autonomic nervous system are well estab- 
lished and are reviewed earlier, studies in patients under- 
going heart transplantation suggest that omega-3 PUFAs 
can reduce heart rate independently of vagal activation, 
in addition to reducing mean arterial pressure and syste- 
mic vascular resistance by 25% and reducing left ventri- 
cular hypertrophy and improving diastolic function [18]. 
The optimal doses and ratios of DHA to EPA are dif- 
ficult to decipher. DHA is far more abundant than EPA 
in the myocardium [13]. DHA alone or in combination 
with EPA may be more important for protection against 
dysrhythmias and cardiovascular disease than EPA alone. 
Although the beneficial effects on dysrhythmias seem to 
occur at lower doses, the relative risk of cardiovascular 
disease has been shown to be related with baseline blood 
levels of omega-3 PUFAs [19-21]. In addition, other 
surrogate CV markers (arterial pressure, endothelial re- 
laxation and attenuated vascular relaxation, and lipopro- 
teins) may be more improved with high doses of DHA 
than with similar doses of EPA [22]. Our results showed 
that omega-3 fatty acids appear to have a small, dose 
dependent, hypotensive effect, the extent of which seems 
to be dependent on the degree of hypertension. In a meta- 
analysis, Morris et al. found a significant reduction in 
blood pressure of 3.4/2.0 mmHg in studies with hyper- 
tensive subjects who consumed 5.6 g/day of omega-3 
fatty acids [23]. However this may happen at the cost of 
adverse reactions in such a high dose. Omega-3 fatty 
acids in such high doses are not recommended for treat- 
ment of hypertension [24]. In our study in according to 
previously an increased intake of Omega-3 fatty acids 
since to 3 gram/day reduced blood pressure by 5 to 10%. 
In our previous studies we demonstrated that when sus- 
tained, weight loss, albeit modest, led to a 22% reduction 
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in the risk for hypertension among middle-aged adults, 
and a 26% reduction in risk in older adults without dif- 
ference of sex [25,26]. DHA may have greater benefits 
than EPA. However, high intakes of omega-3 fatty acids 
per day may be necessary to obtain clinically relevant 
effects, and at this dose level, there is an increased risk of 
bleeding [27]. Therefore, a qualified healthcare provider 
should be consulted prior to starting treatment with sup- 
plements. In according to Mori et al. clinical trials in 
humans have shown that eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) have different haemo- 
dynamic properties; docosahexaenoic acid may be more 
favourable in lowering blood pressure and heart rate, as 
well as improving vascular function [28]. However, the 
effects of EPA and DHA may also differ depending on 
the target population [28]. 
6. Conclusion 
Our analyses indicate that the diet supplementation with 
a relatively high dose of ω-3 PUFAs 3 g/die, can lead to 
clinically relevant blood pressure reduction in individuals 
with untreated normal - high hypertension with and with- 
out metabolic syndrome, without difference of sex and 
age, during 2 years of retrospectively study. In this study 
there was no significant change in weight, and waist cir- 
cumference nor in fasting plasma glucose. Furthermore 
we believe that the field of genomics may be important 
in explaining dietary response via “Mendelian randomi- 
zation” and interactions between diet and genotype. Re- 
search needs to be conducted in different part of the 
world to better understand the responses of different po- 
pulation to diet. Further studies will be needed to address 
the potential benefits of assessing blood levels of omega- 
3 PUFAs to determine its role in dosing adjustments and 
its value in cardiovascular protection. Convincing evi- 
dence from extensive research over the past three dec- 
ades points out the potential beneficial effects of omega- 
3 PUFAs in primary prevention. 
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